CARBOGEN AMCIS Names Dr. Mojmir Vavrecka Chief Operating Officer

BUBENDORF, Switzerland (March 1, 2010) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has appointed Dr. Mojmir Vavrecka as chief operating officer, effective today.

In his new role, Dr. Vavrecka will oversee manufacturing activities and technology development. He will report directly to Nick Green, president of the global contract research and manufacturing services (CRAMS) for Dishman Pharmaceuticals and Chemicals Ltd., CARBOGEN AMCIS’ parent company.

“We are pleased to welcome Dr. Vavrecka to the CARBOGEN AMCIS team. His experience in both research & development and manufacturing will enhance our drive for operational efficiency in our European organization,” said Green.

Dr. Vavrecka has more than 18 years of experience in the pharmaceutical sector and has a strong academic background in synthetic organic chemistry. Previously, Dr. Vavrecka served as site director for SAFC Phama (UK), overseeing manufacturing, project management, process development and quality control. Prior to this appointment, he served as head of chemical production for Fluka (Switzerland) and worked for Hoffmann La Roche AG (Basel, Switzerland) as plant and validation manager. He also holds a Ph.D. in chemistry from the University of Zürich.

“I am looking forward to working with CAROGEN AMCIS and the Dishman Group,” said Dr. Vavrecka. “The group offers an exciting range of technologies and geographies to support drug development throughout the product lifecycle.”

The addition of Dr. Vavrecka follows CARBOGEN AMCIS’ November expansion of late phase service offerings and high-potency manufacturing at its Swiss sites.

CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.

Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and commercial API manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.